Follow Us TR

News Details

ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer

About ESSA Pharma Inc.
  • NASDAQ: $EPIX
  • Notified: $6.10
  • 07:01 EDT

Price Chart